CTI BioPharma Corp (NASDAQ:CTIC) stock went up double digit on Friday.
On Friday, CTIC stock moved up 10.43% to end the session at $2.54. More than 1.25 million shares exchanged hands for the day, compared to its average volume of 1.03 million shares. The stock opened at $2.31 and moved within a range of $2.2900 – 2.5800.
CTIC Business Description
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need.
In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.
|SHARES OUTSTANDING||93.28 M|
|SHARE FLOAT (%)||85.93 M (92.12%)|
|% HELD BY INSTITUTIONS||35.57|
Recent Stock Performance
|+/- EMA(20)||2.35 (+8.09%)|
|+/- SMA(50)||2.58 (-1.55%)|
|+/- SMA(200)||2.72 (-6.62%)|
|CCI20||84.7817||Buy||Chaikin Money Flow||-0.2674||Sell|
|MACD||-0.0987||Sell||Money Flow Index||27.3216||Buy|
|STOCH (14,3)||90.6977||OverBought||STOCH RSI||1.0000||OverBought|